1. Labeling for biosimilar products Publication: Silver Spring, MD : Center for Drug Evaluation and Research, July 2018 Subject(s): Biosimilar PharmaceuticalsDrug Labeling -- standardsHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
2. Questions and answers on biosimilar development and the BPCI Act Publication: Silver Spring, MD : Center for Drug Evaluation and Research, September 2021 Subject(s): Biosimilar PharmaceuticalsDrug DevelopmentUnited StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug AdministrationUnited States.
3. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2022 Subject(s): Biosimilar PharmaceuticalsDrug Costs -- legislation & jurisprudenceGovernment RegulationMedicare Part D -- economicsUnited StatesUnited States. Department of Health and Human ServicesCenters for Medicare & Medicaid Services (U.S.)
